Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2018 17:15 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
January 04, 2018 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule

ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
December 11, 2017 10:45 ET | Source: MacroGenics, Inc.

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting

Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohortData supports combination with MGA012 (anti-PD-1) to potentially enhance...
December 05, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte

ROCKVILLE, MD, Dec. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 15, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Names Dr. Jay Siegel to its Board of Directors

ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 13, 2017 16:01 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 13, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 10, 2017 08:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017

ROCKVILLE, Maryland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 08, 2017 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results

ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 01, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2017 Financial Results Conference Call

ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 8, 2017, the Company will release its financial results for the...
November 01, 2017 09:05 ET | Source: MacroGenics, Inc.

MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting

ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...